Abstract-Previous studies have found pulse pressure (PP), a marker of arterial stiffness, to be an independent predictor of atrial fibrillation (AF) in general and hypertensive populations. We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy. In 8810 patients with neither a history of AF nor AF at baseline, Minnesota coding of electrocardiograms confirmed new-onset AF in 353 patients (4.0%) during mean 4.9 years of follow-up. In multivariate Cox regression analyses, baseline and in-treatment PP and baseline and in-treatment systolic blood pressure predicted new-onset AF, independent of baseline age, height, weight, and Framingham Risk Score; sex, race, and treatment allocation; and in-treatment heart rate and Cornell product. PP was the strongest single blood pressure predictor of new-onset AF determined by the decrease in the Ϫ2 Log likelihood statistic, in comparison with systolic blood pressure, diastolic blood pressure, and mean arterial pressure. When evaluated in the same model, the predictive effect of systolic and diastolic blood pressures together was similar to that of PP. In this population of patients with hypertension and left ventricular hypertrophy, PP was the strongest single blood pressure predictor of new-onset AF, independent of other risk factors. Key Words: arrhythmia Ⅲ atenolol Ⅲ blood pressure Ⅲ hypertension Ⅲ losartan Ⅲ structural heart disease A trial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, and the prevalence is increasing. 1 In the Rotterdam study, the prevalence of AF varied from 0.7% in the age group 55 to 59 years to 17.8% in those aged Ն85 years.
A trial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, and the prevalence is increasing. 1 In the Rotterdam study, the prevalence of AF varied from 0.7% in the age group 55 to 59 years to 17.8% in those aged Ն85 years. 2 AF incidence increases with age, 3 and other risk factors include diabetes, obesity, hypertension, left ventricular hypertrophy (LVH), coronary heart disease, congestive heart failure, valvular heart disease, and increased left atrial size by echocardiography. [4] [5] [6] AF is associated with a 4-to 5-fold increased risk of ischemic stroke 7, 8 and with a nearly doubled cardiovascular mortality risk. 9 Prevention of AF is thus of great importance, and hypertension is currently the most prevalent, potentially modifiable risk factor, accounting for Ϸ14% to 22% of AF cases. 4, 10, 11 Increased pulse pressure (PP), defined as the difference between systolic blood pressure (SBP) and diastolic blood pressure (DBP), is a marker of arterial stiffness. 12 Studies have found PP to be an independent predictor of new-onset AF in both general 13 and hypertensive 14 populations. Mitchell et al 13 showed that increased baseline PP was the single blood pressure (BP) component most predictive of AF in 5331 participants (Ϸ23% on antihypertensive treatment; Ϸ1.2% with electrocardiograpic LVH [ECG-LVH]) during Ϸ20 years of follow-up in the Framingham Heart Study and indicated that the relation between BP and incident AF is potentially related, specifically, to the pulsatile component of BP as assessed by PP. In a study by Ciaroni et al, 14 increased PP (measured by 24-hour ambulatory BP measurement) during antihypertensive treatment was associated with an increased risk of new-onset AF, independent of age, sex, body mass index, and SBP in 597 patients with essential hypertension followed for Ϸ7 years. A pathophysiological explanation may be that arterial stiffness increases with age, resulting in increased PP and increased pulsatile load on the heart, 15 promoting LVH, 16 left ventricular diastolic dysfunction, 17, 18 and increased left atrial size, 19 possibly leading to fibrosis and electric remodeling in the left atrium and, eventually, AF. In a study by Goette et al, 20 patients with permanent AF had increased amount of atrial fibrosis; however, whether atrial fibrosis induces AF or is a consequence of AF is still unknown.
To our knowledge, the relation between baseline PP and PP during antihypertensive treatment and risk of new-onset AF has not yet been evaluated in high-risk patients with hypertension and ECG-LVH. Therefore, the goals of this prespecified Losartan Intervention For Endpoint (LIFE) reduction in hypertension substudy were to investigate the predictive value of higher baseline and in-treatment brachial PP for new-onset AF in patients with hypertension and LVH and to perform a thorough comparison of the predictive value of PP to that of other BP components such as SBP, DBP, and mean arterial pressure (MAP), using the Framingham study by Mitchell et al as a model.
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Methods
Study Design and Population
The LIFE study 21, 22 enrolled 9193 patients with essential hypertension (mean sitting brachial BP: 160 to 200 mm Hg systolic, 95 to 115 mm Hg diastolic, or both) and ECG-LVH (determined by Cornell voltage-duration product 23, 24 and/or Sokolow-Lyon voltage criteria, 25 ) randomized to losartan-versus atenolol-based therapy. (For further details, please see http://hyper.ahajournals.org.) New-onset AF was a prespecified secondary end point. The present analyses included 8810 patients with neither a history of AF nor AF on their baseline ECG. New-onset AF was identified by Minnesota coding of annual in-study ECGs at the core laboratory at Sahlgrenska University Hospital/Östra, Göteborg, Sweden.
21,26
Statistical Analyses
Statistical analyses were performed by the investigators using SPSS version 16.0 (SPSS Inc). Data are presented as meanϮstandard deviation (SD) for continuous variables and as proportions for categorical variables. Brachial PP was calculated as the difference between SBP and DBP. MAP was calculated as DBP plus one third of PP. Baseline characteristics in patients grouped according to quartiles of baseline PP were compared using analysis of variance (ANOVA) for continuous variables and Pearson 2 statistics for categorical variables. Annual measurements of mean PP, SBP, DBP, and MAP were compared using general linear models to account for the within-subject correlation. The incidence of new-onset AF according to quartiles of baseline PP was illustrated in an unadjusted Kaplan-Meier curve.
In the primary analyses, possible associations between baseline PP or PP during antihypertensive therapy and the risk of developing new-onset AF were analyzed using Cox proportional hazards regression analyses. 27, 28 Baseline PP was entered as a continuous covariate, and in-treatment PP (baseline and subsequent routine measurements of PP during follow-up) was entered as a time-varying continuous covariate into univariate and multivariate Cox regression models. Additional covariates in the multivariate model were selected based on being significant univariate predictors that continued to be significant predictors in stepwise forward and backward multivariate analyses. Possible correlations between BP components were analyzed using Pearson correlation coefficient. A 2-tailed PϽ0.05 was required for statistical significance. All study data reside in a database with the authors.
Results
Patient Population and Blood Pressures
In 8810 patients (46% men) at risk of developing new-onset AF, mean baseline PP was 76.5Ϯ15. Mean BP values at baseline and during follow-up are displayed in Figure 1 . At baseline, mean SBP was 174.3Ϯ14.3 mm Hg, mean DBP was 97.9Ϯ8.8 mm Hg, and average MAP was 123.3Ϯ8.1 mm Hg. In patients followed for at least 4 years, 41.3% had a reduction in PP Ն15.5 mm Hg (1 SD of the baseline mean), 79.8% had a reduction in SBP Ն14.3 mm Hg (1 SD), 80.2% had a reduction in DBP Ն8.8 mm Hg (1 SD), and 87.8% had a reduction in MAP Ն8.1 mm Hg (1 SD).
Baseline 
Multivariate Cox Regression Analyses
ECG confirmed new-onset AF in 353 (4.0%) of 8810 patients during a mean follow-up of 4.9Ϯ0.9 years. Figures 2 and 3 present the incidence of AF by quartiles of baseline PP.
Results of the multivariate Cox regression model examining the predictive effect of baseline and in-treatment PP for new-onset AF are presented in Model 2 of Table 2 and in  Table S2 (see http://hyper.ahajournals.org). Baseline PP was associated with a 39% (95% confidence interval [CI], 22% to 58%; PϽ0.001) increased risk of new-onset AF per 15.5 mm Hg (SD) increase, and in-treatment PP was associated with a 33% (95% CI, 18% to 50%; PϽ0.001) increased risk of new-onset AF per SD increase in a model adjusting for baseline age, height, weight, and Framingham Risk Score (FRS); sex, race, and a treatment group indicator (atenolol versus losartan), entered as continuous or categorical covariates; and in-treatment heart rate and ECG-LVH by Cornell product, entered as time-varying continuous covariates. Sex was a significant univariate predictor and was included in the multivariate Cox regression model for biological reasons, even though it was not significant in multivariate analyses. Smoking, diabetes, previous myocardial infarction, and body mass index did not predict new-onset AF; however, replacing height and weight with body mass index in the multivariate model did not alter the results. Baseline total cholesterol, potassium, and urine albumin-creatinine ratio were signifi- cant univariate predictors and were significant in the multivariate model; however, the model did not change when these covariates were excluded. Cox proportional hazards models for PP in comparison with other BP components are presented in Table 2 . All 10 models were adjusted for baseline age, height, weight, and FRS; sex, race and treatment allocation; and in-treatment heart rate and ECG-LVH by Cornell product. When comparing single BP components in parallel multivariate models, adjusting for the same covariates, baseline and in-treatment PP (Models 1 and 2) and baseline and in-treatment SBP (Models 3 and 4), in addition to intreatment MAP adjusted for baseline MAP (Model 8), were significant independent predictors of new-onset AF. Baseline and in-treatment DBP were not significant predictors (Models 5 and 6). The initial Ϫ2 Log likelihood was 5773.6 for the multivariate model, with baseline age, height, weight, and FRS; sex, race, and treatment allocation; and in-treatment heart rate and ECG-LVH by Cornell product. This model was used as a basis to evaluate decrease in Ϫ2 Log likelihood when introducing BP measures. Baseline and in-treatment PP (Model 2) were the strongest single component predictors (Ϫ2 Log likelihood 5739.6; 2 ϭ34.0; 2 df, PϽ0.001); however, when entering baseline and in-treatment SBP and DBP into 1 model (Model 9), the model fit was equally good as for the baseline and in-treatment PP model: Ϫ2 Log likelihood 5739.4 ( 2 ϭ34.2; dfϭ4; PϽ0.001) compared with 5739.6. The model with baseline and in-treatment SBP alone (Model 4) had a Ϫ2 Log likelihood of 5750.2, and adding baseline and in-treatment DBP to the model (Model 9) thus induced a significant improvement ( 2 ϭ10.8; dfϭ2; PϽ0.01). In model 9, baseline and in-treatment SBP and DBP were all significant predictors of new-onset AF; however, the effects of SBP and DBP were opposite. Adding baseline and in-treatment MAP to the model with baseline and in-treatment PP did not change the model fit (Ϫ2 Log likelihood 5739.4 for Model 10 and 5739.6 for Model 2), and baseline and in-treatment MAP were not significant predictors in this model. When forcing baseline and in-treatment PP, SBP, and DBP into the same model, the HRs for DBP were not calculated owing to excess colinearity (rϷ1.0) with PP and SBP. In the same model, baseline PP had a higher 2 (Wald score) than baseline SBP ( 2 8.7 versus 0.01), and in-treatment PP was a stronger predictor than in-treatment SBP ( 2 7.2 versus 0.08). PP was also computed as a categorical variable, with quartiles of baseline PP (quartile 4 versus quartiles 1 to 3). When adjusted for baseline age, height, weight, and FRS; sex, race, and treatment allocation; and in-treatment heart rate and ECG-LVH by Cornell product, baseline PP quartile 4 (Ն87.5 mm Hg) was associated with a 67% (95% CI, 32% to 211%; PϽ0.001) higher risk of new-onset AF compared with quartiles 1 to 3. This result was strengthened when we also adjusted for in-treatment PP in the same model (HR, 1.98; 95% CI, 1.55 to 2.52; PϽ0.001).
There were no significant interactions between baseline or in-treatment PP and other BP components or between baseline or in-treatment PP and baseline age, height, weight, and FRS; sex, race, and treatment allocation; and in-treatment heart rate and ECG-LVH by Cornell product. There were significant interactions between in-treatment heart rate and weight (Pϭ0.03) and in-treatment heart rate and race (Pϭ0.003) in all 10 models (Table 2) . In model 9, there were significant interactions between weight and in-treatment SBP (Pϭ0.03) and weight and in-treatment DBP (Pϭ0.01). In model 10, there were significant interactions between age and in-treatment MAP (Pϭ0.02) and weight and in-treatment MAP (Pϭ0.004).
Discussion
In the present study, increased baseline PP and PP during antihypertensive treatment were associated with an increased risk of incident AF, independent of other predictors of AF in this population (ie, baseline age, height, weight, and FRS; sex, race, and treatment allocation; and in-treatment heart rate and ECG-LVH by Cornell product). Baseline PP quartile 4 (Ն87.5 mm Hg) was associated with a highly significant increase in risk of developing AF during mean 4.9 years of follow-up compared with quartiles 1 to 3.
In comparison with SBP, DBP, and MAP as single BP components, PP was the strongest predictor of incident AF. When we considered the predictive effect of SBP and DBP together, model fit improved significantly and had the same Ϫ2 Log likelihood as the PP model. This is a consequence of the mathematical calculation of PP as the difference between SBP and DBP. When evaluated in the same model, the effects of SBP and DBP were significant but opposite, suggesting that, for a certain value of SBP, lower DBP was associated with an increased risk of new-onset AF. When evaluating PP, SBP, and DBP in the same model, both baseline and in-treatment PP had higher 2 (Wald score) than SBP. This supports the finding that PP is the strongest single BP measure for predicting incident AF in our study; however, it should be interpreted with caution, considering the high correlations between the BP components in this specific model. In-treatment MAP was associated with incident AF when adjusted for baseline MAP and the above-mentioned AF risk factors. Entering MAP into the same model as PP did not improve model fit; baseline and in-treatment MAP were not significant, and the HRs of baseline and in-treatment PP were unaltered. Thus, PP predicted incident AF independent of MAP.
AF is associated with increased risk of cardiovascular morbidity and mortality. It is highly important to identify modifiable risk factors, as both men and women have an approximate 25% overall lifetime risk of AF. 31 To our knowledge, this is the first study to report a strong, independent association between brachial PP and new-onset AF in patients with hypertension and ECG-LVH. Our results are in agreement with a Framingham Heart Study investigation evaluating PP as a predictor for incident AF in a general population with normal or moderately increased BP. 13 Furthermore, Mitchell et al demonstrated that there is a potential weakness of concentrating on SBP alone and ignoring DBP and PP, and our data support this finding. When evaluating the risk of incident AF in a hypertensive population with ECG-LVH, PP should be considered or, alternatively, SBP and DBP together. PP is simple to calculate as the absolute difference between SBP and DBP.
Increased PP, a marker of advanced vascular aging 32 and arterial stiffness, 12 ,33 may contribute in the structural and electric remodeling of the myocardium, leading to the development of AF, possibly through increased pulsatile load on the heart and increased left atrial size. 19 Studies have shown that reduced distensibility of large arteries parallel cardiac hypertrophy and remodeling in patients with hypertension. 34, 35 Large artery stiffness may increase the workload on the heart similar to volume overload and, perhaps, represent one of the mechanisms by which hypertension leads to eccentric hypertrophy and left atrial enlargement. 35 In a LIFE substudy, there was a significant correlation between baseline brachial PP and left atrial size, independent of age, sex, and body surface area (data not shown). 36 Furthermore, there is much evidence for linking brachial PP to microvascular damage in the heart and other target organs, which, again, may lead to increased peripheral resistance and MAP, further increasing arterial stiffness and central PP. Increased central PP may then further damage small arteries and lead to LVH. 37 Studies have found brachial PP to be a powerful predictor of cardiovascular morbidity and mortality, [38] [39] [40] [41] [42] [43] [44] [45] and the predictive effect increases with age. [42] [43] [44] The present study evaluated brachial PP and not central PP. Noninvasive central PP has been shown to better predict cardiovascular outcomes than brachial PP and to be closer associated with extent of atherosclerosis (carotid plaque burden and intimal-medial thickness, and vascular mass). 
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In conclusion, in patients with hypertension and ECG-LVH in the LIFE study, increased baseline and in-treatment PP were independently associated with increased risk of newonset AF. PP was (in comparison with SBP, DBP, and MAP) the single BP component with the strongest predictive effect.
Limitations
Patients evaluated in the LIFE study were predominantly white and from Western countries. They had hypertension and ECG-LVH and increased risk of cardiovascular events compared with hypertensive subjects without LVH. The results may not be generalizable to normotensives and hypertensives without LVH. BP was measured with a sphygmomanometer, which is considered less accurate than 24-hour ambulatory BP measurement. 43 New-onset AF was a prespecified secondary end point; however, the LIFE study was designed and had statistical power for the primary composite end point, and the HRs for AF require careful interpretation.
Perspectives
In patients with hypertension and ECG-LVH in the LIFE study, increased baseline and in-treatment PP were independently associated with new-onset AF. PP was (in comparison with SBP, DBP and MAP) the single BP component with the strongest predictive effect, supporting the hypothesis that the relation between BP and incident AF is related specifically to the pulsatile component of BP as assessed by PP. 13 Furthermore, SBP and DBP together had a predictive effect similar to the predictive effect of PP, reflecting the definition of PP. In-treatment MAP was significantly associated with newonset AF when adjusted for baseline MAP and the mentioned risk factors; however, the predictive effect was weaker than for PP or for SBP and DBP evaluated together. This result may imply that the association between MAP (the steady component of BP) and AF is weak. When evaluating risk of AF in patients with hypertension and ECG-LVH, both baseline PP and PP during antihypertensive treatment, alternatively SBP and DBP together, should be considered. Furthermore, lowering of PP may prevent new-onset AF in patients with hypertension and LVH; however, this must be further explored in randomized clinical trials.
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Novelty and Significance
What Is New?
• To our knowledge, this is the first study to report a strong, independent association between baseline pulse pressure and pulse pressure during antihypertensive treatment and new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy.
What Is Relevant?
• In 8810 patients in this randomized (losartan versus atenolol) treatment trial, pulse pressure (the pulsatile component of blood pressure and a marker of arterial stiffness) was the strongest single blood pressure predictor for atrial fibrillation compared with systolic blood pressure, diastolic blood pressure, and mean arterial pressure.
Summary
When evaluating risk of atrial fibrillation in patients with hypertension and left ventricular hypertrophy, both baseline pulse pressure and pulse pressure during antihypertensive treatment should be considered.
